NCT04961541: A trial that was reported late by Novavax
This trial has reported, although it was 126 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04961541 |
|---|---|
| Title | A Phase 1/2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a Quadrivalent Hemagglutinin Nanoparticle Influenza and SARS-CoV-2 rS Nanoparticle Combination Vaccine With Matrix M1™ Adjuvant in Healthy Participants ≥ 50 to ≤ 70 Years of Age |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 8, 2021 |
| Completion date | Dec. 22, 2021 |
| Required reporting date | Dec. 22, 2022, midnight |
| Actual reporting date | April 27, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | 126 |